PURPOSE: Investigate the efficacy and safety of multipattern incobotulinumtoxinA injections
in children/adolescents with lower-limb cerebral palsy (CP)-related spasticity. METHODS …

Background This randomized, phase 3 study with double-blind main period (MP) and open-
label extension (OLEX; NCT02002884) assessed incobotulinumtoxinA safety and efficacy …

PURPOSE: The open-label phase 3 “Treatment with IncobotulinumtoxinA in Movement
Open-Label”(TIMO) study investigated longer-term safety and efficacy of …

Abstract Background IncobotulinumtoxinA (Xeomin®) is a botulinum neurotoxin type A with
established efficacy in the treatment of upper-limb spasticity in adults. This retrospective …

Background IncobotulinumtoxinA (Xeomin®) is a purified botulinum neurotoxin type A
formulation, free from complexing proteins, with proven efficacy and good tolerability for the …

Background The only two preparations of botulinum toxin A for which there are published
evidences of efficacy in children with cerebral palsy are onabotulinum toxin A (Botox®) and …

In this study, we compared the longterm efficacy and tolerability of two dosage regimens of
the potent botulinum toxin type A (BoNTA; Dysport; Ipsen Ltd, Slough, UK) in children with …

Botulinum neurotoxin typeA (BoNTA) has been used in association with other
interventions in the management of spasticity in children with cerebral palsy (CP) for almost …

Background: Cerebral palsy (CP) is the most common cause of childhood disability globally.
Botulinum toxin A injections are widely used to manage limb spasticity in children with CP …

The aim of this study was to investigate the use of botulinum toxin type A (BoNT-A) injections
and their efficacy on gross motor function for lower limb spasticity in children with spastic …